期刊文献+

氟西汀合用小剂量奥氮平治疗抑郁症疗效观察 被引量:2

Efficacy of fluoxetine plus olanzapine in the treatment of depression
下载PDF
导出
摘要 目的观察氟西汀合用小剂量奥氮平治疗抑郁症的临床疗效。方法56例符合中国精神障碍分类与诊断标准第3版(CCMD-3)诊断标准的患者,随机分成奥氮平组(对照组)和氟西汀合用小剂量奥氮平组(研究组),共观察8周;于治疗前,治疗后1、2、4、6、8周末采用汉密尔顿抑郁量表(HAMD),副反应量表(TESS)评定疗效和副反应。结果治疗第8周末,研究组疗效显著,研究组与对照组的显效率分别为85.7%和64.3%,差异有显著性(P<0.05);研究组在1周末起效,对照组在2周末起效;治疗后1、2、4、6、8周末两组间HAMD评分差异有显著意义(P<0.05);各周末TESS评分差异均无显著意义(P>0.05)。结论氟西汀合用小剂量奥氮平治疗抑郁症起效快,克服了抗抑郁药本身起效慢的缺点,且疗效优于对照组,不良反应无明显增加。 Objective To evaluate the efficacy of low dosage of olanzapine combined with fluoxetine in treatment of depression. Methods A total of 56 patients of depression diagnosed according to Chinese classification of mental disorders-3 (CCMD-3), were randomly divided into 2 groups : olanzapine group (control group) and olanzapine combined with fluoxetine group(research group). Results After 8 weeks treatment, the percentage of patients with significant efficacy in research group was 85.7%,and that in control group was 64.3%(P〈0.05). The time to response in research group and control group was 1 week and 2 weeks,respectively.The result of HAMD score demonstrated significant difference between two groups at each weekend during the treatment period(P〈0.05).The result of TESS did not show similar difference(P〉0.05). Conclusions The efficacy of fluoxetine combined with low dosage of olanzapin is a fast and effective method to treat depression without additional adverse events.
作者 许佳平
出处 《中国现代医药杂志》 2007年第8期69-71,共3页 Modern Medicine Journal of China
关键词 氟西汀 奥氮平 抑郁症 Fluoxetine Olanzapine Depression
  • 相关文献

参考文献4

二级参考文献10

  • 1[1]Rothschild AJ Bates ks. Olanzapine responsein psychoticdepression.Journal of psychiatry. 1999;60(2): 116~ 118
  • 2[2]GD Tollefson. Depressive symptoms in Schizophrenia. Blol psychia TRY, 1998;43:803~ 810
  • 3[3]Nemer off CB. An ever - increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry, 2000;61 (Supp 13): 19 ~ 25
  • 4[4]Sanger TM, Beashey cm, Tran PV. A double - blind controlled companision of the novel antipsychotic olanzapine versus Naloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological psychiatry, 1998;43(11): 803 ~ 810
  • 5[5]Shelton Rc. A Novel angmentation strategy for treating major depression. American Journal of psychiatry, 2001; 158(1): 131 ~ 134
  • 6Bymaster FP.In vitro and in vivo biochemistry of olanzapine.J Clin Psychiatry,1997,58 Suppl 10:28-36.
  • 7Kapur S,Zipursky RB,Remington G,et al.Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine,risperidone,and olanzapine in schizophrenia.Am J Psychiatry,1999,156:286-293.
  • 8Shelton RC,Tollefson GD,Tohen M,et al.A novel augmentation strategy for treating resistant major depression.Am J psychiatry,2001,158:131-134.
  • 9舒良,刘平.新型非典型抗精神病药奥氮平[J].中华精神科杂志,1999,32(2):123-123. 被引量:49
  • 10金卫东,苏宗荣,赵汉清.新型抗精神病药在抑郁症治疗中的应用[J].国外医学(精神病学分册),2001,28(2):100-105. 被引量:40

共引文献29

同被引文献18

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部